Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.

Hematol Oncol · 2021 · PMC8451799 · PMID 33739461

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significancep = 0.06so close (0.05 < p ≤ 0.1)

27.0 months [95% CI 21.7–47.3] p = 0.02; Figure 1D ), with a borderline significance ( p = 0.06) for advanced stage.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.